株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Rytary/IPX066(パーキンソン病)- 予測と市場分析

Rytary/IPX066 (Parkinson's Disease) - Forecast and Market analysis to 2022

発行 GlobalData 商品コード 301436
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
Rytary/IPX066(パーキンソン病)- 予測と市場分析 Rytary/IPX066 (Parkinson's Disease) - Forecast and Market analysis to 2022
出版日: 2014年03月31日 ページ情報: 英文 88 Pages
概要

パーキンソン病は、動作緩慢、筋硬直、振戦、姿勢の不安定で特徴づけられる進行性の症状です。2番目に高頻度の神経変性障害で、どの年齢層にも影響を及ぼす可能性があり、有病率は加齢とともに上昇し、高齢者によく見られます。動作緩慢には、ドーパミン療法がかなり効果的ですが、いくつかのアンメットニーズが残されています。

当レポートでは、パーキンソン病の治療薬であるRytary/IPX066について調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • QOL
  • 症状

第4章 疾病の管理

  • 概要
  • 治療の概要
  • パーキンソン病の評価規模

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 機会とアンメットニーズ

  • 概要
  • 運動合併症の治療
  • 非運動合併症の治療
  • 神経保護/予防維持薬
  • 製剤の改善
  • 信頼性の高いバイオマーカー
  • 臨床試験設計の改善

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 Rytary/IPX066

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC401DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Rytary, also known as IPX066, is a levodopa-based product for the treatment of early and advanced Parkinson's disease. It was developed by the generics manufacturer Impax Laboratories and contains a capsule with different-sized beads that dissolve at different rates, releasing a 1:4 ratio of carbidopa: levodopa.

Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Rytary including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Rytary for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Rytary performance
  • Obtain sales forecast for Rytary from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's Disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Treatment of Motor Complications - Dyskinesias and OFF Episodes
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Non-Motor Symptoms and Dementia
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Neuroprotective/Disease-Modifying Agents
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Identification of Reliable Biomarkers
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Clinical Trial Design
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Rytary/IPX066

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Parkinson's Disease Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Compliance Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
    • 9.4.7. Pricing of Pipeline Agent
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 9: Leading Treatments for Parkinson's Disease, 2014
  • Table 10: Unmet Need and Opportunity in Parkinson's Disease
  • Table 11: Dyskinesia Pipeline, 2014
  • Table 12: Dementia Pipeline, 2014
  • Table 13: Parkinson's Disease-Modifying Therapeutics Pipeline, 2014
  • Table 14: Product Profile - Rytary
  • Table 15: Rytary SWOT Analysis, 2014
  • Table 16: Global Sales Forecasts ($m) for Rytary, 2012-2022

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
  • Figure 3: Pharmacokinetics of Levodopa
  • Figure 4: Parkinson's Disease - Phase II-III Pipeline, Segmented by Indication, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson's Disease, 2012-2022
Back to Top